We are live on ! Find out more
GILD icon

Gilead Sciences

1,525 hedge funds and large institutions have $66.4B invested in Gilead Sciences in 2017 Q1 according to their latest regulatory filings, with 133 funds opening new positions, 601 increasing their positions, 701 reducing their positions, and 157 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.66% less ownership

Funds ownership: 75.43%74.76% (-0.66%)

3% less funds holding

Funds holding: 1,5731,525 (-48)

3% less funds holding in top 10

Funds holding in top 10: 9188 (-3)

7% less capital invested

Capital invested by funds: $71.2B → $66.4B (-$4.83B)

14% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 701

15% less first-time investments, than exits

New positions opened: 133 | Existing positions closed: 157

35% less call options, than puts

Call options by funds: $1.45B | Put options by funds: $2.24B

Holders
1,525
Holders Change
-48
Holders Change %
-3.05%
% of All Funds
37.95%
Holding in Top 10
88
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-3.3%
% of All Funds
2.19%
New
133
Increased
601
Reduced
701
Closed
157
Calls
$1.45B
Puts
$2.24B
Net Calls
-$793M
Net Calls Change
-$355M
Name Holding Trade Value Shares
Change
Change in
Stake
ANRIA
1026
American National Registered Investment Advisor
Texas
$846K -$12.3K -175 -1%
MNBTD
1027
Moody National Bank Trust Division
Texas
$843K -$12.3K -175 -1%
NL
1028
NWAM LLC
Washington
$842K +$76.2K +1,084 +10%
IH
1029
IFC Holdings
Florida
$841K -$69.1K -982 -7%
PGFC
1030
Peapack-Gladstone Financial Corp
New Jersey
$837K +$356K +5,062 +70%
PCM
1031
Parsons Capital Management
Rhode Island
$836K +$13.4K +190 +2%
BDF
1032
Balasa Dinverno & Foltz
$836K +$183K +2,608 +27%
ED
1033
Exane Derivatives
France
$829K -$493K -7,008 -36%
BWM
1034
BerganKDV Wealth Management
Minnesota
$827K +$101K +1,442 +13%
BST
1035
Bath Savings Trust
Maine
$824K -$1.34M -19,075 -61%
SAM
1036
Shikiar Asset Management
New York
$818K -$854K -12,150 -50%
BPCE
1037
Bank Pictet & Cie (Europe)
Germany
$810K -$34.7K -493 -4%
ARMC
1038
American Research & Management Company
Massachusetts
$807K +$512K +7,275 +158%
AI
1039
Atria Investments
North Carolina
$805K -$1.25M -17,747 -60%
CCA
1040
Checchi Capital Advisers
California
$802K +$33.8K +480 +4%
MHS
1041
M Holdings Securities
Oregon
$801K +$71.4K +1,015 +9%
LWM
1042
Lyons Wealth Management
Florida
$801K +$81K +1,152 +11%
MMPW
1043
Mitchell McLeod Pugh & Williams
Alabama
$798K -$6.33K -90 -0.8%
ACH
1044
ArrowMark Colorado Holdings
Colorado
$797K -$58.8K -836 -7%
WIM
1045
Waverton Investment Management
United Kingdom
$794K -$71.1M -1,011,603 -99%
GXMC
1046
Global X Management Company
New York
$789K +$175K +2,495 +27%
CG
1047
Caprock Group
Idaho
$784K -$16K -228 -2%
RB
1048
Rodgers Brothers
Pennsylvania
$779K +$225K +3,200 +39%
CIAS
1049
Capital Investment Advisory Services
North Carolina
$778K -$3.45K -49 -0.4%
BP
1050
BBR Partners
New York
$777K +$37.6K +535 +5%

GILD Hedge Fund Activity: Q1 2017 in Review

1,525 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2017, worth a combined $66.4B — down 6.8% from $71.2B a quarter earlier.

Sellers outnumbered buyers: 157 funds closed out of GILD and 133 opened new positions — a net loss of 24 holders — while 701 trimmed existing stakes and 601 added.

The largest buyer was BlackRock, adding an estimated $6.99B. The largest seller was Fidelity Investments, cutting an estimated $1.15B.

  • 1,525 institutional investors held Gilead Sciences (GILD) as of Q1 2017, down from 1,573 in Q4 2016.
  • Funds reported $66.4B of Gilead Sciences stock for Q1 2017, down 6.8% quarter-over-quarter.
  • 133 funds opened new Gilead Sciences positions in Q1 2017 and 157 closed out, a net change of -24 holders.
  • The largest Gilead Sciences buyer in Q1 2017 was BlackRock, an estimated $6.99B added.
  • The largest Gilead Sciences seller in Q1 2017 was Fidelity Investments, an estimated $1.15B sold.

Based on aggregated 13F filings for Q1 2017.